NINLARO CAPSULE

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

IXAZOMIB (IXAZOMIB CITRATE)

Dostopno od:

TAKEDA CANADA INC

Koda artikla:

L01XG03

INN (mednarodno ime):

IXAZOMIB

Odmerek:

2.3MG

Farmacevtska oblika:

CAPSULE

Sestava:

IXAZOMIB (IXAZOMIB CITRATE) 2.3MG

Pot uporabe:

ORAL

Enote v paketu:

3

Tip zastaranja:

Prescription

Terapevtsko območje:

ANTINEOPLASTIC AGENTS

Povzetek izdelek:

Active ingredient group (AIG) number: 0158410001; AHFS:

Status dovoljenje:

APPROVED

Datum dovoljenje:

2016-08-04

Lastnosti izdelka

_NINLARO (as ixazomib citrate) capsules _
_Page 1 of 42_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
NINLARO
®
Ixazomib capsules
Capsules, 4 mg, 3 mg and 2.3 mg ixazomib (as ixazomib citrate), Oral
Antineoplastic Agent
Takeda Canada Inc.
22 Adelaide Street West, Suite 3800
Toronto Ontario M5H 4E3
Date of Initial Authorization:
Aug 3, 2016
Date of Revision:
Feb 02, 2024
Submission Control Number: 279731
NINLARO® and the NINLARO Logo® are registered trademarks of
Millennium Pharmaceuticals,
Inc.
TAKEDA™ and the TAKEDA Logo® are registered trademarks of Takeda
Pharmaceutical Company
Limited, used under license.
_NINLARO (as ixazomib citrate) capsules _
_Page 2 of 42_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Skin
02/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2.
CONTRAINDICATIONS
...................................................................................................
4
3.
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 4
4
DOSAGE AND ADMINISTRATION
..................................................................................
5
4.1
Dosing Considerations
...........................................